Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could aspirin and ketamine be the next depression breakthrough?

NCT ID NCT05615948

Symptom relief Sponsor: Theresa Jacob, PhD, MPH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small study tested whether taking aspirin and ketamine together by mouth can help people with treatment-resistant depression. Fifteen adults who had not gotten better with standard antidepressants received the combination alongside their usual medication. Researchers measured changes in depression symptoms using a standard rating scale over one week.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a combination of aspirin and ketamine taken by mouth
What this could lead to
If it works, this could offer a new, easy-to-take option for people with depression that hasn't responded to standard antidepressants.
What could go wrong
This was a very small, open-label study with only 15 people, so results may not apply widely. The combination has not been tested in larger, more rigorous trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

15 people

The number who actually took part.

Started

Dec 2022

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients with Treatment Resistant Depression with Montgomery-Asberg Depression Rating Scale score \>22 upon presentation to the clinic * Treatment Resistant Depression is defined as Major Depressive Disorder that does not cease after at least 6 week trial of another class of antidepressants * Unipolar Depression Exclusion Criteria: * Adult patients with recent or current suicidal ideation with an intent to act, homicidal ideations with an intent to act * History of Bipolar Disorder, Obsessive Compulsive Disorder, antisocial personality disorder, borderline personality disorder, and congestive cardiac failure * Uncontrolled hypertension (BP \>140 mm Hg systolic and/or \>90 mm Hg diastolic on two separate readings at the time of screening) or on 2 medications for hypertension * Patients with unstable vital signs (systolic blood pressure \<90 or\>160 mm Hg, pulse rate \<50 or \>150 beats/min, and respiration rate \<10 or \>30 breaths/min), * History of Gastrointestinal hemorrhage, renal and hepatic insufficiency * Allergy to Ketamine or Aspirin * Active Substance Abuse Disorder * Active psychosis * Active Peptic Ulcer Disease * Lithium Therapy * Swallowing difficulty * Consumption of Aspirin or NSAID's within 6 hours of arrival to the site * Previous participation in this study; a patient may not re-enroll in another study while in this study * Pregnant or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Analgesia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

agnosia Depression Depressive Disorder, Treatment-Resistant major depressive disorder pain agnosia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Analgesia Analgesics, non-narcotic Anti-inflammatory agents Anti-inflammatory agents, non-steroidal Central nervous system depressants Depressive symptoms Ketamine Major depressive disorder Neurotransmitter agents Peripheral nervous system agents Physiological effects of drugs Sensory system agents Treatment-resistant depression

Contacts and locations

Locations

  • Maimonides Medical Center

    Brooklyn, New York, 11219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.